
Neuropathic Pain Market
Neuropathic Pain Market Forecasts to 2030 - Global Analysis By Drug Class (Antidepressants, Anticonvulsant, Opioids, Capsaicin, Steroids and Other Drug Classes), Indication, Patient Type, Route of Administration, Distribution Channel and By Geography

According to Stratistics MRC, the Global Neuropathic Pain Market is accounted for $8.24 billion in 2024 and is expected to reach $14.35 billion by 2030 growing at a CAGR of 9.7% during the forecast period. Neuropathic pain is a complex, chronic pain condition that arises due to damage or dysfunction in the nervous system. Diabetes, shingles, multiple sclerosis, and nerve injuries are among the conditions that frequently cause it. This kind of pain can be accompanied by hypersensitivity to touch or temperature changes and is typified by feelings of burning, stabbing, tingling, or numbness. It can be difficult to treat, necessitating a multimodal strategy that may involve drugs, physical therapy, nerve blocks, and counselling. Moreover, a person's quality of life is greatly impacted by the condition, so improving patient outcomes requires early diagnosis and efficient treatment.
According to a narrative review published in the National Institutes of Health's PubMed Central, neuropathic pain does indeed affect approximately 7-10% of the general population.
Market Dynamics:
Driver:
Growing number of neuropathic disorders
Neuropathic pain is often associated with underlying conditions such as diabetes, post-herpetic neuralgia, multiple sclerosis, and traumatic nerve injuries. For instance, studies indicate that about 50% of individuals with diabetes will eventually develop diabetic neuropathy, making the global increase in diabetes a major contributing factor. Furthermore, nerve degeneration is more likely to occur in an aging population, which increases the prevalence of age-related disorders like neuropathy. The need for efficient pain management treatments is fueled by the increasing prevalence of these illnesses. The market for therapies and diagnostic equipment is anticipated to expand in tandem with the rise in the number of people experiencing neuropathic pain.
Restraint:
Absence of effective treatment choices
Even with improvements in neuropathic pain management, there is still a big need for long-term, really effective therapies. Many of the treatments available today only offer partial relief, and some have unfavorable side effects like fatigue, lightheadedness, or digestive problems. For instance, opioid drugs are useful for treating acute pain, but their use in treating chronic pain is restricted due to their high potential for addiction and dependency. Additionally, some patients might not respond to commonly prescribed medications, which can cause frustration and delay in locating an appropriate course of treatment.
Opportunity:
Evolution of personalized medicine
The trend toward personalized medicine is one of the most exciting prospects in the market for neuropathic pain. The genetic, molecular, and environmental factors that contribute to neuropathic pain are becoming better understood as research progresses. More effective and targeted pain relief with fewer side effects may be possible with personalized treatments based on a patient's genetic profile, pain pathways, and reaction to medication. Moreover, businesses are already looking into genetic markers to forecast a patient's reaction to particular neuropathic painkillers. This strategy could significantly increase treatment success rates, cut down on trial and error, and provide patients with more individualized pain management options, making it a very profitable area for innovation.
Threat:
Vigorous competition from generic medicines
The market for neuropathic pain is seriously threatened by the availability of generic medications. There are now generic versions of many drugs used to treat neuropathic pain, including duloxetine, pregabalin, and gabapentin. Since generic medications are usually far less expensive than their branded equivalents, businesses that have created unique formulations have a much smaller chance of making money. Pharmaceutical companies are under pressure to cut prices due to the fierce competition from generics, which can reduce profit margins. Additionally, this price competition will also get more intense as generic versions of neuropathic painkillers continue to hit the market as more patents for these drugs expire.
Covid-19 Impact:
The market for neuropathic pain was significantly impacted by the COVID-19 pandemic, both positively and negatively. As hospitals and clinics concentrated their resources on treating COVID-19 cases, the global healthcare crisis caused disruptions in healthcare systems, including delays in the diagnosis and treatment of neuropathic pain. Patients had less access to specialized pain management therapies as a result of routine appointments and elective procedures being delayed. Financial limitations brought on by the pandemic's economic downturn also made it harder for patients to pay for treatments, particularly those that required sophisticated therapies or procedures.
The Diabetic Neuropathy segment is expected to be the largest during the forecast period
The Diabetic Neuropathy segment is expected to account for the largest market share during the forecast period. This dominance is explained by the high global prevalence of diabetes, which causes diabetic neuropathy in a considerable number of people. The International Diabetes Federation (IDF), for example, projected that by 2022, 643 million adults between the ages of 20 and 79 would have diabetes by 2030, and by 2045, that number would have increased to 783 million. Moreover, the market share of this segment is strengthened by the large number of diabetics, which raises the need for efficient treatments for diabetic neuropathy.
The Adult segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Adult segment is predicted to witness the highest growth rate. The main cause of this growth is the rising incidence of diseases like postherpetic neuralgia and diabetic neuropathy in adults. The International Diabetes Federation (IDF), for example, projected that by 2022, 643 million adults between the ages of 20 and 79 would have diabetes by 2030, and by 2045, that number would have increased to 783 million. Additionally, the market share of this segment is strengthened by the large number of diabetics, which raises the need for efficient treatments for diabetic neuropathy.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share. The main cause of this dominance is the high frequency of neuropathic conditions that are more common in adults, such as diabetic neuropathy, post herpetic neuralgia, and chemotherapy-induced peripheral neuropathy. The development of the market in this area is also greatly influenced by the existence of sophisticated healthcare infrastructure, as well as by greater awareness of and access to treatment options. Furthermore, North America leads the market due to the growing number of people with chronic illnesses like diabetes and the continuous research and development of new pain management treatments.
Region with highest CAGR:
Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR. The increasing prevalence of diabetic neuropathy and other neuropathic conditions, as well as the region's growing healthcare infrastructure and improved access to healthcare, are the main causes of this rapid growth. The need for efficient pain management treatments is also being fueled by rising awareness of neuropathic pain and its available treatments, as well as bettering economic conditions and healthcare spending in nations like China and India. Moreover, the strong growth prediction for the APAC region in the upcoming years is influenced by these factors.
Key players in the market
Some of the key players in Neuropathic Pain market include Abbott Laboratories, Pfizer, Inc, Sanofi S.A., Johnson & Johnson Services, Inc., Novartis AG, Eli Lilly and Company, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., Baxter Healthcare Corporation, Collegium Pharmaceutical, Inc., Mallinckrodt Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Limited, Bristol-Myers Squibb Company and Grunenthal GmbH.
Key Developments:
In December 2024, Teva Pharmaceutical Industries Ltd. announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.
In September 2024, Abbott India Limited has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company Limited to market and distribute ""Vonoprazan"" in India under the brand name ""Vonefi"". Vonoprazan addresses severe acid related disorders like reflux esophagitis through a once daily dose.
In August 2024, Johnson & Johnson1 announced that it has entered into a definitive agreement to acquire V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. Under the terms of the agreement, Johnson & Johnson will acquire V-Wave for an upfront payment of $600 million, subject to customary adjustments, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion.
Drug Classes Covered:
• Antidepressants
• Anticonvulsant
• Opioids
• Capsaicin
• Steroids
• Other Drug Classes
Indications Covered:
• Diabetic Neuropathy
• Spinal Stenosis
• Post-Herpetic Neuralgia
• Chemotherapy-Induced Peripheral Neuropathy
• Other Indications
Patient Types Covered:
• Adult
• Geriatric
• Pediatric
Route of Administrations Covered:
• Oral
• Transdermal
• Intravenous
• Topical
Distribution Channels Covered:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Neuropathic Pain Market, By Drug Class
5.1 Introduction
5.2 Antidepressants
5.2.1 Tricyclic Antidepressants
5.2.2 Serotonin-Noradrenaline Reuptake Inhibitors (SNRI)
5.3 Anticonvulsant
5.4 Opioids
5.5 Capsaicin
5.6 Steroids
5.7 Other Drug Classes
6 Global Neuropathic Pain Market, By Indication
6.1 Introduction
6.2 Diabetic Neuropathy
6.3 Spinal Stenosis
6.4 Post-Herpetic Neuralgia
6.5 Chemotherapy-Induced Peripheral Neuropathy
6.6 Other Indications
7 Global Neuropathic Pain Market, By Patient Type
7.1 Introduction
7.2 Adult
7.3 Geriatric
7.4 Pediatric
8 Global Neuropathic Pain Market, By Route of Administration
8.1 Introduction
8.2 Oral
8.3 Transdermal
8.4 Intravenous
8.5 Topical
9 Global Neuropathic Pain Market, By Distribution Channel
9.1 Introduction
9.2 Hospital Pharmacy
9.3 Retail Pharmacy
9.4 Online Pharmacy
10 Global Neuropathic Pain Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Abbott Laboratories
12.2 Pfizer, Inc
12.3 Sanofi S.A.
12.4 Johnson & Johnson Services, Inc.
12.5 Novartis AG
12.6 Eli Lilly and Company
12.7 GlaxoSmithKline PLC
12.8 Teva Pharmaceutical Industries Ltd.
12.9 Baxter Healthcare Corporation
12.10 Collegium Pharmaceutical, Inc.
12.11 Mallinckrodt Pharmaceuticals
12.12 Sun Pharmaceutical Industries Ltd
12.13 Glenmark Pharmaceuticals Limited
12.14 Bristol-Myers Squibb Company
12.15 Grunenthal GmbH
List of Tables
1 Global Neuropathic Pain Market Outlook, By Region (2022-2030) ($MN)
2 Global Neuropathic Pain Market Outlook, By Drug Class (2022-2030) ($MN)
3 Global Neuropathic Pain Market Outlook, By Antidepressants (2022-2030) ($MN)
4 Global Neuropathic Pain Market Outlook, By Tricyclic Antidepressants (2022-2030) ($MN)
5 Global Neuropathic Pain Market Outlook, By Serotonin-Noradrenaline Reuptake Inhibitors (SNRI) (2022-2030) ($MN)
6 Global Neuropathic Pain Market Outlook, By Anticonvulsant (2022-2030) ($MN)
7 Global Neuropathic Pain Market Outlook, By Opioids (2022-2030) ($MN)
8 Global Neuropathic Pain Market Outlook, By Capsaicin (2022-2030) ($MN)
9 Global Neuropathic Pain Market Outlook, By Steroids (2022-2030) ($MN)
10 Global Neuropathic Pain Market Outlook, By Other Drug Classes (2022-2030) ($MN)
11 Global Neuropathic Pain Market Outlook, By Indication (2022-2030) ($MN)
12 Global Neuropathic Pain Market Outlook, By Diabetic Neuropathy (2022-2030) ($MN)
13 Global Neuropathic Pain Market Outlook, By Spinal Stenosis (2022-2030) ($MN)
14 Global Neuropathic Pain Market Outlook, By Post-Herpetic Neuralgia (2022-2030) ($MN)
15 Global Neuropathic Pain Market Outlook, By Chemotherapy-Induced Peripheral Neuropathy (2022-2030) ($MN)
16 Global Neuropathic Pain Market Outlook, By Other Indications (2022-2030) ($MN)
17 Global Neuropathic Pain Market Outlook, By Patient Type (2022-2030) ($MN)
18 Global Neuropathic Pain Market Outlook, By Adult (2022-2030) ($MN)
19 Global Neuropathic Pain Market Outlook, By Geriatric (2022-2030) ($MN)
20 Global Neuropathic Pain Market Outlook, By Pediatric (2022-2030) ($MN)
21 Global Neuropathic Pain Market Outlook, By Route of Administration (2022-2030) ($MN)
22 Global Neuropathic Pain Market Outlook, By Oral (2022-2030) ($MN)
23 Global Neuropathic Pain Market Outlook, By Transdermal (2022-2030) ($MN)
24 Global Neuropathic Pain Market Outlook, By Intravenous (2022-2030) ($MN)
25 Global Neuropathic Pain Market Outlook, By Topical (2022-2030) ($MN)
26 Global Neuropathic Pain Market Outlook, By Distribution Channel (2022-2030) ($MN)
27 Global Neuropathic Pain Market Outlook, By Hospital Pharmacy (2022-2030) ($MN)
28 Global Neuropathic Pain Market Outlook, By Retail Pharmacy (2022-2030) ($MN)
29 Global Neuropathic Pain Market Outlook, By Online Pharmacy (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY

We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?

Assured Quality
Best in class reports with high standard of research integrity

24X7 Research Support
Continuous support to ensure the best customer experience.

Free Customization
Adding more values to your product of interest.

Safe & Secure Access
Providing a secured environment for all online transactions.

Trusted by 600+ Brands
Serving the most reputed brands across the world.